Compare Stocks: NVTA, NTRA, VCYT, RDNT, and CDNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$48.97 -2.3%	$39.39	$12.37 ▼ $53.67	$2.59B	2.38	1.11 million shs	1.25 million shs
NTRA Natera	$320.76 -0.4%	$288.65	$157.43 ▼ $343.18	$46.41B	1.54	1.48 million shs	1.21 million shs
NVTA Invitae	$0.00	$0.00	$0.02 ▼ $0.02	$80K	1.59	23.72 million shs	N/A
RDNT RadNet	$75.52 -0.4%	$68.10	$50.82 ▼ $85.84	$5.97B	1.4	722,558 shs	762,970 shs
VCYT Veracyte	$43.43 +0.6%	$51.51	$29.38 ▼ $60.91	$3.47B	1.95	1.29 million shs	872,988 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	-2.27%	-3.60%	+12.03%	+119.50%	+258.49%
NTRA Natera	-0.37%	-4.74%	+19.79%	+51.41%	+90.64%
NVTA Invitae	0.00%	0.00%	0.00%	0.00%	0.00%
RDNT RadNet	-0.40%	-1.74%	+18.41%	+45.59%	+5.24%
VCYT Veracyte	+0.56%	-1.39%	-6.24%	-10.80%	+43.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$48.97 -2.3%	$39.39	$12.37 ▼ $53.67	$2.59B	2.38	1.11 million shs	1.25 million shs
NTRA Natera	$320.76 -0.4%	$288.65	$157.43 ▼ $343.18	$46.41B	1.54	1.48 million shs	1.21 million shs
NVTA Invitae	$0.00	$0.00	$0.02 ▼ $0.02	$80K	1.59	23.72 million shs	N/A
RDNT RadNet	$75.52 -0.4%	$68.10	$50.82 ▼ $85.84	$5.97B	1.4	722,558 shs	762,970 shs
VCYT Veracyte	$43.43 +0.6%	$51.51	$29.38 ▼ $60.91	$3.47B	1.95	1.29 million shs	872,988 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	-2.27%	-3.60%	+12.03%	+119.50%	+258.49%
NTRA Natera	-0.37%	-4.74%	+19.79%	+51.41%	+90.64%
NVTA Invitae	0.00%	0.00%	0.00%	0.00%	0.00%
RDNT RadNet	-0.40%	-1.74%	+18.41%	+45.59%	+5.24%
VCYT Veracyte	+0.56%	-1.39%	-6.24%	-10.80%	+43.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDNA CareDx	2.57	Moderate Buy	$47.75	-2.49% Downside
NTRA Natera	2.82	Moderate Buy	$319.38	-0.43% Downside
NVTA Invitae	0.00	N/A	N/A	N/A
RDNT RadNet	2.89	Moderate Buy	$90.00	19.17% Upside
VCYT Veracyte	2.82	Moderate Buy	$54.33	25.11% Upside

Current Analyst Ratings Breakdown

Latest NVTA, NTRA, CDNA, VCYT, and RDNT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2026	RDNT RadNet	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$65.00 ➝ $79.00
8/24/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/13/2026	CDNA CareDx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C)
8/13/2026	NTRA Natera	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$315.00 ➝ $365.00
8/13/2026	RDNT RadNet	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	NTRA Natera	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$305.00 ➝ $350.00
8/12/2026	NTRA Natera	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$290.00 ➝ $360.00
8/12/2026	NTRA Natera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	NTRA Natera	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$249.00 ➝ $363.50
8/11/2026	RDNT RadNet	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$90.00 ➝ $94.00
8/11/2026	VCYT Veracyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDNA CareDx	$458.09M	5.53	$0.01 per share	7,693.37	$8.23 per share	5.95
NTRA Natera	$2.31B	20.05	N/A	N/A	$12.64 per share	25.38
NVTA Invitae	$481.58M	0.00	N/A	N/A	$0.42 per share	0.00
RDNT RadNet	$2.04B	2.91	$3.21 per share	23.52	$17.71 per share	4.26
VCYT Veracyte	$517.15M	6.75	$1.50 per share	29.00	$17.27 per share	2.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDNA CareDx	-$21.35M	$2.07	23.66	77.73	N/A	24.23%	2.87%	2.17%	11/3/2026 (Estimated)
NTRA Natera	-$208.16M	-$1.36	N/A	32,076.00	N/A	-7.11%	-11.38%	-7.87%	11/5/2026 (Estimated)
NVTA Invitae	-$3.11B	-$5.38	N/A	N/A	N/A	-299.14%	-6,100.71%	-19.68%	N/A
RDNT RadNet	-$18.65M	-$0.27	N/A	86.80	N/A	-0.93%	2.61%	0.91%	11/9/2026 (Estimated)
VCYT Veracyte	$66.35M	$1.41	30.80	28.20	N/A	20.37%	9.26%	8.61%	11/3/2026 (Estimated)

Latest NVTA, NTRA, CDNA, VCYT, and RDNT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	RDNT RadNet	$0.2014	$0.29	+$0.0886	$0.10	$610.87 million	$622.72 million
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
NVTA Invitae	N/A	N/A	N/A	N/A	N/A
RDNT RadNet	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDNA CareDx	N/A	4.58	4.51
NTRA Natera	N/A	3.00	2.85
NVTA Invitae	N/A	2.39	2.25
RDNT RadNet	0.94	1.48	1.48
VCYT Veracyte	N/A	9.16	8.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDNA CareDx	N/A
NTRA Natera	99.90%
NVTA Invitae	61.28%
RDNT RadNet	77.90%
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
CDNA CareDx	2.40%
NTRA Natera	5.05%
NVTA Invitae	0.74%
RDNT RadNet	5.14%
VCYT Veracyte	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDNA CareDx	740	51.73 million	50.49 million	Optionable
NTRA Natera	6,140	144.14 million	136.87 million	Optionable
NVTA Invitae	1,700	267.01 million	284.37 million	No Data
RDNT RadNet	11,264	78.70 million	74.65 million	Optionable
VCYT Veracyte	790	80.39 million	79.11 million	Optionable

NVTA, NTRA, VCYT, RDNT, and CDNA Headlines

Recent News About These Companies

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 1 at 4:05 PM | globenewswire.com

Veracyte, Inc. $VCYT Shares Sold by Moore Capital Management LP

September 1 at 5:44 AM | marketbeat.com

Wellington Management Group LLP Lowers Position in Veracyte, Inc. $VCYT

September 1 at 5:12 AM | marketbeat.com

161,973 Shares in Veracyte, Inc. $VCYT Bought by Corient Private Wealth LP

August 31 at 3:44 AM | marketbeat.com

Alyeska Investment Group L.P. Lowers Stock Position in Veracyte, Inc. $VCYT

August 31 at 3:04 AM | marketbeat.com

269,806 Shares in Veracyte, Inc. $VCYT Purchased by Jupiter Topco LLC

August 30 at 5:04 AM | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Takes $1.58 Million Position in Veracyte, Inc. $VCYT

August 30 at 3:37 AM | marketbeat.com

437,604 Shares in Veracyte, Inc. $VCYT Purchased by Bank of New York Mellon Corp

August 30 at 3:20 AM | marketbeat.com

Legal & General Group Plc Invests $50.40 Million in Veracyte, Inc. $VCYT

August 29, 2026 | marketbeat.com

Formula Growth Ltd. Purchases Shares of 27,000 Veracyte, Inc. $VCYT

August 28, 2026 | marketbeat.com

Analyzing Wesana Health (OTCMKTS:WSNAF) & Veracyte (NASDAQ:VCYT)

August 28, 2026 | americanbankingnews.com

Freestone Grove Partners LP Makes New Investment in Veracyte, Inc. $VCYT

August 28, 2026 | marketbeat.com

Veracyte, Inc. (VCYT) Stock Price, News, Quote & History - Yahoo Finance

August 28, 2026 | finance.yahoo.com

50,484 Shares in Veracyte, Inc. $VCYT Bought by Cibc World Market Inc.

August 27, 2026 | marketbeat.com

Bamco Inc. NY Invests $38.22 Million in Veracyte, Inc. $VCYT

August 27, 2026 | marketbeat.com

Veracyte (VCYT) Receives a Buy from Piper Sandler

August 26, 2026 | theglobeandmail.com

Is it Worth Adding Veracyte Stock to Your Portfolio Now?

August 26, 2026 | zacks.com

123,015 Shares in Veracyte, Inc. $VCYT Acquired by EFG International AG

August 26, 2026 | marketbeat.com

Castleark Management LLC Buys New Position in Veracyte, Inc. $VCYT

August 26, 2026 | marketbeat.com

VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?

August 25, 2026 | zacks.com

Deutsche Bank AG Buys New Shares in Veracyte, Inc. $VCYT

August 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVTA, NTRA, VCYT, RDNT, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

$48.97 -1.14 (-2.27%)

As of 09/1/2026 04:00 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Natera NASDAQ:NTRA

$320.76 -1.20 (-0.37%)

As of 09/1/2026 04:00 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Invitae NYSE:NVTA

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

RadNet NASDAQ:RDNT

$75.52 -0.30 (-0.40%)

As of 09/1/2026 04:00 PM Eastern

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Veracyte NASDAQ:VCYT

$43.43 +0.24 (+0.56%)

As of 09/1/2026 04:00 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVTA, NTRA, CDNA, VCYT, and RDNT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVTA, NTRA, CDNA, VCYT, and RDNT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVTA, NTRA, VCYT, RDNT, and CDNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVTA, NTRA, VCYT, RDNT, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

Natera NASDAQ:NTRA

Invitae NYSE:NVTA

RadNet NASDAQ:RDNT

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools